Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. (2014)
Attributed to:
Epidemiological and statistical research on health problems of developing countries: MRC Tropical Epidemiology Group
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0114602
PubMed Identifier: 25490675
Publication URI: http://europepmc.org/abstract/MED/25490675
Type: Journal Article/Review
Volume: 9
Parent Publication: PloS one
Issue: 12
ISSN: 1932-6203